Clinical Trials Logo

Clinical Trial Summary

In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.


Clinical Trial Description

In December 2019, viral pneumonia caused by a novel beta-coronavirus (2019-nCoV) outbroke in Wuhan, China. Part of patients rapidly progress severe acute respiratory failure with substantial mortality, making it imperative to develop an efficient treatment for severe 2019-nCoV pneumonia besides the supportive care.

Intravenous immunoglobulin (IVIG) has been shown to improve the treatment effect and prognosis of severe infection over the past decades with its capacity of proving passive immunity and anti-inflammatory, immunomodulatory effect. We hypothesized that IVIG therapy would improve the prognosis of severe and critically ill patients with 2019-nCoV.

This single-center, randomized, open-label, controlled trial will evaluate the efficacy and safety of IVIG therapy in patients with severe or critically ill 2019-nCoV respiratory disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04261426
Study type Interventional
Source Peking Union Medical College Hospital
Contact Taisheng Li
Phone 010-69155086
Email litsh@263.net
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date February 10, 2020
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Suspended NCT04334967 - Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4
Not yet recruiting NCT04264858 - Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients N/A
Withdrawn NCT04272710 - Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Completed NCT04260594 - Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus Phase 4
Active, not recruiting NCT04273763 - Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) N/A
Not yet recruiting NCT04270383 - Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
Terminated NCT04261907 - Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection N/A
Recruiting NCT04255017 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Phase 4
Recruiting NCT04254874 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia Phase 4
Not yet recruiting NCT04356508 - COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Phase 2
Terminated NCT04321928 - Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary N/A